Advancing Therapeutic Strategies for Neurodegenerative Diseases

We are pleased to highlight significant progress in targeting protein aggregation in neurodegenerative disorders, following the presentation of compelling preclinical proof-of-concept data for PRI-101 by our partner, Priavoid GmbH, at AD/PD 2026.

PRI-101, an innovative all-D-peptide therapeutic, has demonstrated the ability to actively disassemble α-synuclein aggregates, one of the key pathological drivers in Parkinson’s disease and related synucleinopathies. Notably, these findings were validated across multiple experimental systems, including advanced human brain organoid models, where reductions in pathological α-synuclein species were accompanied by measurable functional improvements.

At OrganoTherapeutics, we are proud to have contributed to this work through the development and application of cutting-edge human brain organoid platforms. These systems enable more accurate modeling of synucleinopathy-relevant biology and support the generation of translational insights.

This collaboration underscores several important advances in the field:

• The increasing relevance of human organoids as predictive preclinical platforms

• The value of mechanistically targeted approaches to protein aggregation

• The potential to bridge the gap between early discovery and clinical translation

We look forward to continuing our collaboration with Priavoid to advance disease-modifying therapies for neurodegenerative diseases.

For more information on Priavoid’s work, click here.